NEW YORK, NY / ACCESSWIRE / August 17, 2018 / U.S. markets bounced back on Thursday after Walmart and Cisco reported upbeat quarterly earnings. The Dow Jones Industrial Average jumped 1.58 percent to close at 25,558.73, while the S&P 500 Index have gained 0.79 percent to close at 2,840.69. The Nasdaq Composite Index increased 0.42 percent to close at 7,806.52.
“Earnings out of Walmart are very positive for the market as it is a reflection not just of Walmart’s online growth but it offers a positive snapshot of the U.S. consumer,” said chief market strategist at Prudential Financial, Quincy Krosby.
RDI Initiates Coverage on:
Array BioPharma Inc.
AVEO Pharmaceuticals, Inc.
Array BioPharma's stock jumped 3.5% Thursday, to close the day at $14.21. The stock recorded a trading volume of 2,615,220 shares, which was above its three months average volume of 2,535,895 shares. In the last year, Array BioPharma's shares have traded in a range of 8.50 - 20.21. The share price has gained 67.18% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $16.15 is below its 200-day moving average of $16.26. Shares of Array BioPharma have fallen roughly 16.56 percent in the past month and are up 11.02 percent year-to-date.
Access RDI's Array BioPharma Inc. Research Report at:
On Thursday, shares of AVEO Pharmaceuticals recorded a trading volume of 2,009,324 shares, which was below the three months average volume of 2,389,346 shares. The stock ended the day 3.67% higher at $2.26. The share price has fallen 46.7% from its 52 week high with a 52 week trading range of 1.86 - 4.24. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.33 is below its 200-day moving average of $2.54. Shares of AVEO Pharmaceuticals have fallen roughly 20.7 percent in the past month and are down 19 percent year-to-date.
Access RDI's AVEO Pharmaceuticals, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.